Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- (-) Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- (-) Health Spending
- Health Spend Management
- (-) High-Deductible Health Plans
- (-) Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Display Only
Showing 206 Results
Focus on Whole Person Quality Care When Implementing Budget Caps
The National Pharmaceutical Council hosted a virtual panel discussion on state decisions to implement budget caps and the strategies, challenges, and the relevance of these decisions on patient…
Savvy Employers Alter Status Quo to Address Drugs, Deductibles and Disincentives for Treatment
Thanks to an IRS rule, high-deductible health plans with health savings accounts can now cover an expanded list of preventive services and drugs before patients meet their plan’s annual out-of-pocket…
U.S. vs. EU: Not a Direct Comparison When It Comes to Drug Pricing
It’s challenging to compare U.S. and ex-U.S. countries’ drug prices and health spending, given the big differences in the countries’ economies, health care systems, payment mechanisms and disease…
NPC Comments on Most Favored Nation (MFN) Model [CMS-5528-IFC]
NPC explains how using payment models based on pricing in other countries could have a negative impact on patient outcomes, access to treatments and future innovation.
Assessing Consumer and Employer Willingness to Pay for New Medical Technologies
This study examines whether health care consumers and large employers would be willing to continue to pay for new medical technologies associated with significant improvements in patient health…
Racial and Socioeconomic Disparities: Ignoring Inequitable Benefit Design Is Not an Option
In a new commentary published in BenefitsPro, Kimberly Westrich, NPC Vice President for Health Services Research, and Bruce Sherman, MD, medical advisor for the National Alliance of Healthcare…
Health Plan Enrollment May be Open, but Drug Coverage Is Still a Black Box for Many People
Most people choose coverage based mainly on the price – the health care premiums and deductibles. But a narrow focus on health care costs overlooks the overall quality of the health plan. Consumers…
Accumulating Barriers to Care: Double Jeopardy for US Patients
In a column for PharmaBoardroom, Dan Leonard, National Pharmaceutical Council President and CEO, Kimberly Westrich, Vice President of Health Services Research, and Brian Sils, Senior Research…
A Wish List for the Health Care Sector in 2020
NPC President and CEO Dan Leonard reflects on the health policy issues he hopes will be addressed in 2020.
Principles for Sound Pharmacy and Therapeutics Practices: What’s Next
AMCP's Partnership Forum, “Principles for Sound Pharmacy and Therapeutics (P&T) Practices: What’s Next?” focused on the current state of P&T committees, challenges faced by these committees…
Updated Tools Developed to Communicate High-Quality Information About New Treatments and Inform Health Plan Coverage and Reimbursement
NPC said that with the release of the new AMCP Format for Formulary Submissions, biopharmaceutical manufacturers and health plans will have a practical guide to exchange clinical and economic…
NPC Weighs in on CMS Oncology Care First Model
NPC submitted comments regarding the Centers for Medicare and Medicaid Services Center for Medicare and Medicaid Innovation informal request for information on the Oncology Care First Model.
Little Consistency in Evidence Cited by Commercial Health Plans for Specialty Drug Coverage
Evidence cited by payers in coverage decisions for specialty medicines varies significantly, with health plans only citing the same study in 15% of health plan coverage policies for a given drug and…
Good News for Patients With High-Deductible Health Plans
In his commentary for Specialty Pharmacy Times, NPC President and CEO Dan Leonard explains how research supported by NPC and conducted by VBID Health demonstrates the health and cost benefits of…
Three Themes You’ll Take Away From “Health Spending: Moving From Theory to Action”
Health spending is increasing in the United States, but what steps are being taken to address this challenge? Join Health Affairs and the National Pharmaceutical Council (NPC) on September 11 for an…
Best Ideas Aren’t Always (or Often) From Washington
In his latest commentary for Chain Drug Review, National Pharmaceutical Council President and CEO Dan Leonard explores the health care concerns and ideas for improvement discussed at recent regional…